InTheCloud Podcast🎙️Episode 1
LogRhythm Axon's Kevin Eley goes pulls no punches!
LogRhythm Axon's Kevin Eley goes pulls no punches!
Welcome to another episode of the Cloud Community “talking heads” series. Get an honest view on the Gartner SIEM Magic Quadrant, the real cost benefits of cloud, and much more as Kevin Eley, VP of Sales for the UK and EMEA at LogRhythm joins us.
The series is intended to equip our members with the knowledge they need to assess how different solutions stack up against the real-life challenges they are facing. We are inviting some technology experts to showcase their technologies in a direct, straight-talking forum where we'll challenge and press for answers, not jargon, from the perspective of a buyer.
LogRhythm Axon are also offering Cloud Community readers an exclusive opportunity to put their claims to the test in a free 5 day trial. So if you already have a SIEM and are open to the possibility for change even if there is no project or budget assigned yet, it's worth looking at.
During the session you'll hear Kevin's direct approach on:
LogRhythm Axon offers a cloud-native SaaS SIEM platform. It blends the advantages of both SaaS and cloud-native approaches, freeing security teams from infrastructure management to focus on threat detection and response.
Looking Under the Hood of the LogRhythm and Exabeam Merger
LogRhythm Axon's Joanne Wong outlines promises made means promises kept
July 2024 quarterly launch - LogRhythm Axon
Demo: Gain visibility and threat detection across hybrid environments
Vendor wins the SIEM category at the 2024 Cybersecurity Excellence Awards
95% of organisations revamped defence strategies in the last year
LogRhythm Axon's Matt Willems talks flexibility of cloud-native SIEM and much more!
Pull back the curtain on the leading cloud-native SaaS SIEM
The latest cloud-native SIEM strategies & new solutions in this webcast from LogRhythm
Vulnerabilities to be aware of, what’s to come with GenAI
LogRhythm Axon's Guy Grieve untangles cloud-native SIEM.
Let us know what you think about the article.
